ATOS vs. PRTC, SEPN, ORKA, TRML, MBX, MGTX, SIGA, ZYBT, UPXI, and ALT
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include PureTech Health (PRTC), Septerna (SEPN), Oruka Therapeutics (ORKA), Tourmaline Bio (TRML), MBX Biosciences (MBX), MeiraGTx (MGTX), SIGA Technologies (SIGA), Zhengye Biotechnology (ZYBT), Upexi (UPXI), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Atossa Therapeutics vs.
Atossa Therapeutics (NASDAQ:ATOS) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 7.6% of Atossa Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Atossa Therapeutics had 5 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Atossa Therapeutics and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.76 beat Atossa Therapeutics' score of 0.60 indicating that PureTech Health is being referred to more favorably in the news media.
Atossa Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
Atossa Therapeutics presently has a consensus target price of $6.17, indicating a potential upside of 596.41%. PureTech Health has a consensus target price of $45.00, indicating a potential upside of 140.58%. Given Atossa Therapeutics' higher possible upside, equities research analysts plainly believe Atossa Therapeutics is more favorable than PureTech Health.
PureTech Health's return on equity of 0.00% beat Atossa Therapeutics' return on equity.
Atossa Therapeutics received 236 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 65.68% of users gave Atossa Therapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote.
Atossa Therapeutics has higher earnings, but lower revenue than PureTech Health.
Summary
Atossa Therapeutics beats PureTech Health on 8 of the 14 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATOS) was last updated on 6/10/2025 by MarketBeat.com Staff
